Results 1 to 10 of about 3,315 (167)

Aggressive prolactinomas in men are associated with visual disturbances and pituitary hormone deficiencies [PDF]

Scientific Reports
Prolactinomas/lactotroph pituitary neuroendocrine tumors are ten times less frequent in men than in women and their characteristics are less well known.
Everardo J. Díaz-López, Rocío Villar-Taibo, Eva Fernández-Rodríguez, Laura Cotovad-Bellas, Alberto Pena-Dubra, Teresa Prado-Moraña, Gemma Rodríguez-Carnero, Kelly Vargas-Osorio, José Manuel Cameselle-Teijeiro, Ignacio Bernabéu   +9 more
doaj   +2 more sources

Study of Clinical Profile and Early Response to Dopamine Agonist Therapy in Patients of Hyperprolactinemia: Experience at a Tertiary Care Centre of Nepal [PDF]

Indian Journal of Endocrinology and Metabolism
Introduction: Pathological hyperprolactinemia is medically treatable condition with dopamine agonist therapy. This research was aimed to study clinical profiles of patients of hyperprolactinemia started on cabergoline and assess clinical, biochemical ...
Richa Nepal, Manil R. Bajracharya, Budda B. Karki, Bikash B. S. Adhikari, Kushal P. Wasti, Anjal Bisht   +5 more
doaj   +2 more sources

Cognitive Function and Serum Hormone Levels Are Associated with Gray Matter Volume Decline in Female Patients with Prolactinomas

Frontiers in Neurology, 2018
Background and objectiveCognitive impairments have been reported in patients with hyperprolactinemia; however, there is a lack of knowledge of brain structure alterations relevant to hyperprolactinemia in prolactinomas. Thus, we aimed to identify changes
Shun Yao, Shun Yao, Jian Song, Junfeng Gao, Pan Lin, Ming Yang, Ming Yang, Kashif Rafiq Zahid, Yan Yan, Chenglong Cao, Pan Ma, Hui Zhang, Zhouyue Li, Cheng Huang, Huichao Ding, Guozheng Xu, Guozheng Xu   +16 more
doaj   +3 more sources

Somatic SF3B1 hotspot mutation in prolactinomas

Nature Communications, 2020
The genetic basis of prolactinomas remains poorly understood. Here, the authors find a recurrent hotspot somatic mutation in the splicing factor 3 subunit B1 (SF3B1 R625H ) in prolactinomas, and show that this mutation causes aberrant splicing of ESRRG ...
Chuzhong Li, Weiyan Xie, Jared S. Rosenblum, Jianyu Zhou, Jing Guo, Yazhou Miao, Yutao Shen, Hongyun Wang, Lei Gong, Mingxuan Li, Sida Zhao, Sen Cheng, Haibo Zhu, Tao Jiang, Shiying Ling, Fei Wang, Hongwei Zhang, Mingshan Zhang, Yanming Qu, Qi Zhang, Guilin Li, Junmei Wang, Jun Ma, Zhengping Zhuang, Yazhuo Zhang   +24 more
doaj   +2 more sources

Pituitary hormone deficiencies in prolactinomas: prevalence, predictors, and functional recovery [PDF]

Frontiers in Endocrinology
IntroductionTo evaluate the prevalence of pituitary hormone deficiencies in patients with prolactinomas, identify clinical and radiological predictors of non-gonadal hypopituitarism at diagnosis, and evaluate the potential for pituitary function recovery
Antonio Prinzi, Antonio Prinzi, Ginevra Fava, Ignazio Bacchi, Federica Spitali, Antonio Galvano, Giorgio Arnaldi, Francesco Frasca, Valentina Guarnotta, Pasqualino Malandrino   +9 more
doaj   +2 more sources

A new and useful tool for differentiating prolactinomas from non-functioning pituitary adenomas: a pilot study of the cabergoline disconnection test [PDF]

Einstein (São Paulo)
Objective: Clinical, imaging, and laboratory differentiation between non-functioning pituitary adenomas (NFPAs) and prolactinomas can be challenging in clinical practice because of their similar presentation and eventual overlap in prolactin levels.
Stefano Alvarenga Galliano, Matheo Augusto Morandi Stumpf, Nara L. Queiroz, Eduardo Henrique Rodrigues Ferreira, Flora Ladeira Craveiro, Christiane Gruetzmacher, Gilberto Ochman da Silva, Valter Angelo Sperling Cescato, Eduardo Arnaldo Silva Vellutini, Malebranche Berardo Carneiro Cunha-Neto, Rafael Loch Batista, Andrea Glezer   +11 more
doaj   +2 more sources

Cystic versus non-cystic prolactinoma: clinical, hormonal, radiological, and remission outcomes in Basrah [PDF]

Frontiers in Endocrinology
IntroductionProlactinomas are the most common functional pituitary adenomas. Cystic prolactinomas, characterized by substantial cystic components on magnetic resonance imaging (MRI) scans, may exhibit different clinical behaviors and treatment outcomes ...
Khulood Abed Reman, Haider Ayad Alidrisi, Ali Hussain Ali Alhamza, Hassan Falah Alobaidy, Abbas Ali Mansour   +4 more
doaj   +2 more sources

Theta oscillations in prolactinomas: Neurocognitive deficits in executive controls

NeuroImage: Clinical, 2020
Impairment of cognitive functions has been reported in prolactinomas. However, the electrophysiological mechanisms of response activation and response inhibition in prolactinomas remain unclear. We recorded participants’ scalp electroencephalography (EEG)
Chenglong Cao, Wen Wen, Binbin Liu, Pan Ma, Sheng Li, Guozheng Xu, Jian Song   +6 more
doaj   +3 more sources

Impact of Tumor Size on Prolactinoma Characteristics and Treatment Outcomes: A Study of a Tunisian Cohort [PDF]

Biomedicines
Issues: The clinical and paraclinical characteristics of prolactinomas differ mainly according to sex and tumor size. Drug treatment with dopamine agonists (ADs) has a crucial role in the management of prolactinomas.
Mouna Elleuch, Hamdi Frikha, Fatma Loukil, Khouloud Boujelben, Dhouha Ben Salah, Nabila Mejdoub Rekik   +5 more
doaj   +2 more sources

Prolactinomas [PDF]

JAMA, 2021
Hyperprolactinemia, defined by a level of serum prolactin above the standard upper limit of normal range, is a common finding in clinical practice and prolactinomas are the main pathological cause. Prolactinomas lead to signs and symptoms of hormone oversecretion, such as galactorrhea and hypogonadism, as well as symptoms of mass effect, including ...
Pauline P, Huynh, Lisa E, Ishii, Masaru, Ishii   +2 more
openaire   +4 more sources